OPDUALAG (nivolumab and relatlimab) is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma.1
Please consult the OPDUALAG Product Monograph or click HERE for important information relating to:
• Contraindications in patients with hypersensitivity to nivolumab or relatlimab or to any ingredient in the formulation
• The most serious warnings and precautions regarding severe/fatal immune-mediated adverse reactions (imARs), and administration under the supervision of physicians experienced in the treatment of cancer
• Other relevant warnings and precautions regarding monitoring, frequency and signs and symptoms of imARs, infusion-related reactions, risk of solid organ transplant rejection, hemophagocytic lymphohistiocytosis (HLH), Graft-versus-host disease; Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); driving or operating machinery; use in patients with severe hepatic or severe renal impairment; use in pregnancy and breastfeeding
• Conditions of clinical use, adverse reactions, drug interactions and dosing instructions (particularly do not shake)
* Clinical significance unknown.